Core Viewpoint - Omeros Corporation is discussing its newly approved drug, YARTEMLEA, and its expectations regarding demand, manufacturing capacity, and commercial sales [2][3]. Group 1: Company Operations - The conference call includes forward-looking statements about Omeros' operations and assets, particularly focusing on YARTEMLEA [2]. - Management's current expectations and beliefs are subject to risks and uncertainties that could lead to actual results differing from projections [3]. Group 2: Drug Approval and Market Expectations - YARTEMLEA has received approval, and the company anticipates significant demand and commercial sales [2]. - The discussion will cover aspects such as reimbursement and development in additional indications for YARTEMLEA [2].